Understanding multiple myeloma heterogeneity by utilizing NGS

Siobhan Glavey, MD, PhD, Royal College of Surgeons in Ireland, Dublin, Ireland, highlights the need for more targeted molecular testing for multiple myeloma in clinics in Ireland. Prof. Glavey believes that molecular technologies, such as next-generation sequencing (NGS), will greatly help to explain the large heterogeneity seen clinically in multiple myeloma. This interview was recorded virtually.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.